Topoisomerase II alpha amplification may predict benefit from adjuvant anthracyclines in HER2 positive early breast cancer

被引：0
|
作者：
Edurne Arriola
Socorro Maria Rodriguez-Pinilla
Maryou B. K. Lambros
Robin L. Jones
Michelle James
Kay Savage
Ian E. Smith
Mitch Dowsett
Jorge S. Reis-Filho
机构：
[1] Institute of Cancer Research,The Breakthrough Breast Cancer Research Centre
[2] Royal Marsden Hospital,Department of Academic Biochemistry
[3] Royal Marsden Hospital,Breast Unit
来源：
Breast Cancer Research and Treatment | 2007年 / 106卷
关键词：
Anthracyclines; Breast cancer; Chromogenic ; hubridisation; HER2; Topoisomerase II alpha;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：181 / 189
页数：8
相关论文
共 50 条
  • [31] HER2 positive breast cancer
    Gianni, Luca
    Bianchini, Giampaolo
    CANCER RESEARCH, 2023, 83 (05)
  • [32] TIMP-1 in Combination with HER2 and TOP2A for Prediction of Benefit from Adjuvant Anthracyclines in High Risk Breast Cancer Patients.
    Hertel, P. B.
    Tu, D.
    Ejlertsen, B.
    Jensen, M-B
    Balslev, E.
    Jiang, S.
    O'Malley, F. P.
    Pritchard, K. I.
    Shepherd, L. E.
    Bartels, A.
    Brunner, N.
    Nielsen, T. O.
    CANCER RESEARCH, 2011, 71
  • [33] Topoisomerase II alpha gene amplification is a favorable prognostic factor in patients with HER2-positive metastatic breast cancer treated with trastuzumab
    George Fountzilas
    Christos Christodoulou
    Mattheos Bobos
    Vassiliki Kotoula
    Anastasia G Eleftheraki
    Ioannis Xanthakis
    Anna Batistatou
    George Pentheroudakis
    Nikolaos Xiros
    Irene Papaspirou
    Anna Koumarianou
    Pavlos Papakostas
    Dimitrios Bafaloukos
    Dimosthenis V Skarlos
    Konstantine T Kalogeras
    Journal of Translational Medicine, 10
  • [34] Topoisomerase II alpha gene amplification is a favorable prognostic factor in patients with HER2-positive metastatic breast cancer treated with trastuzumab
    Fountzilas, George
    Christodoulou, Christos
    Bobos, Mattheos
    Kotoula, Vassiliki
    Eleftheraki, Anastasia G.
    Xanthakis, Ioannis
    Batistatou, Anna
    Pentheroudakis, George
    Xiros, Nikolaos
    Papaspirou, Irene
    Koumarianou, Anna
    Papakostas, Pavlos
    Bafaloukos, Dimitrios
    Skarlos, Dimosthenis V.
    Kalogeras, Konstantine T.
    JOURNAL OF TRANSLATIONAL MEDICINE, 2012, 10
  • [35] Adjuvant chemotherapy of breast cancers with overexpression or HER2 amplification
    Petit, Thierry
    ONCOLOGIE, 2008, 10 : S64 - S67
  • [36] Cost/effectiveness analysis of adjuvant therapy with trastuzumab in patients with HER2 positive early breast cancer
    Fagnani, Francis
    Colin, Xavier
    Arveux, Patrick
    Coudert, Bruno
    Misset, Jean-Louis
    BULLETIN DU CANCER, 2007, 94 (7-8) : 711 - 720
  • [37] Optimal omission of anthracycline in adjuvant chemotherapy of HER2 positive breast cancer
    Watanuki, R.
    Hayashida, T.
    Yuko, K.
    Kikuchi, M.
    Nakashoji, A.
    Yokoe, T.
    Toyota, T.
    Seki, T.
    Takahashi, M.
    Kitagawa, Y.
    CANCER RESEARCH, 2019, 79 (04)
  • [38] Topoisomerase II alpha as a marker predicting anthracyclines' activity in early breast cancer patients: Ready for the primetime?
    Di Leo, Angelo
    Biganzoli, Laura
    Claudino, Wederson
    Licitra, Sara
    Pestrin, Marta
    Larsimont, Denis
    EUROPEAN JOURNAL OF CANCER, 2008, 44 (18) : 2791 - 2798
  • [39] Adjuvant chemotherapy for elderly HER2/neu positive breast cancer patients
    Miryusupova, G.
    Shayusupov, N.
    BREAST, 2015, 24 : S63 - S63
  • [40] Clinicopathologic Significance of the Intratumoral Heterogeneity of HER2 Gene Amplification in HER2-Positive Breast Cancer Patients Treated With Adjuvant Trastuzumab
    Lee, Hee Jin
    Kim, Joo Young
    Park, So Yeon
    Park, In Ah
    Song, In Hye
    Yu, Jong Han
    Ahn, Jin-Hee
    Gong, Gyungyub
    AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2015, 144 (04) : 570 - 578
12345